FATE
Fate Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $352.01M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.05 |
| EPS (TTM) | $-1.09 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -20.30% |
| ROE | -55.50% |
| Debt/Equity | 42.73 |
| Recommendation | Buy 2.1 |
| Analyst Target | $5.41 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 78.0 |
| Beta | 2.52 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.11 |
| 52-Week Low | $0.91 |
| 50-Day Avg | $2.02 |
| 200-Day Avg | $1.40 |
| Avg Volume | $3.80M |
| Volume | $5.86M |
Performance Analysis
NEUTRALFATE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:09 UTC
Back to Screener Export Report